Conclusions
In our real-world study, our results indicated that the CES1
polymorphism rs8192935 was associated with trough plasma concentrations
of dabigatran. Carriers of the G allele had increased trough plasma
concentrations of dabigatran compared to noncarriers. The ABCB1
polymorphisms rs4148738 and rs1045642 were associated with an increased
risk for major bleeding events. These genetic associations could be
useful for predicting the effect of dabigatran along with the bleeding
risk for individuals, and further studies with larger sample sizes are
needed to verify the findings.